Startups
D. E. Shaw Research (DESRES) is a New York-based drug discovery and computational biochemistry research company developing and using advanced computational technologies to understand the behavior of biologically and pharmaceutically significant molecules at an atomic level of detail, and to design precisely targeted, highly selective drugs for the treatment of various diseases. Among our core technologies is a proprietary special-purpose supercomputer called ANTON® which we designed and constructed to perform molecular dynamics simulations more than 100 times faster than the world's fastest general-purpose supercomputers. DESRES develops and refines advanced biomolecular modeling methods, software, and machine learning techniques on ANTON®, as well as on general-purpose supercomputers, in order to pursue both internal and collaborative drug discovery programs.
Overview
Location
United States, New York
Employees
51-200
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 15, 2023 | Hedge fund D. E. Shaw raises $1.1b for two private market funds | Hedge fund D. E. Shaw Group said on Tuesday it had raised a total of $1.1 billion for two of its new funds focused on investing in private markets. Its private credit-focused fund Diopter received $650 million and is aimed at helping banks ... |
| Oct 10, 2022 | Новая волна ARM-процессоров. Серверы на старте | Судя по всему, процессоры на одном кристалле достигли своего предела. Законы физики и математики не позволяют дальше уменьшать транзисторы. Но это не значит, что развитие электроники остановится, а закону Мура конец. Ничего подобного. После... |
| Apr 7, 2021 | Hedge fund D E Shaw raised $1bn for new private equity fund targeting distressed deals, special situations | Global hedge fund investor D E Shaw has raised $1bn for a new private equity fund targeting stressed and distressed asse |
| Sep 16, 2016 | Protein-motion startup launches armed with $57M to develop drugs, crack cancer code | Molecular-level movies may not spark the imagination of too many directors. But for oncology patients, the imaging techniques Relay is working on represent another front in the effort to crack the code of cancer. The technique that Relay, b... |
| Protein-motion startup launches armed with $57M to develop drugs, crack cancer code | A picture may be worth a thousand words, but when it comes to disease discovery, Bay Area VC firm Third Rock Ventures is betting its money on moving pictures. But instead of Hollywood blockbusters, the San Francisco-based investment firm in... |
Reviews 0
FAQ about D. E. Shaw Research
What has the press written about D. E. Shaw Research?
Parsers VC has collected 6 articles mentioning D. E. Shaw Research, among them “Hedge fund D. E. Shaw raises $1.1b for two private market funds” (Feb 15, 2023) and “Новая волна ARM-процессоров. Серверы на старте” (Oct 10, 2022).
Is D. E. Shaw Research still active?
Yes, D. E. Shaw Research is active; its latest activity on Parsers VC dates from Feb 16, 2023.